Washington Research Foundation

Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington.

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

Mirador Biomedical's team of experienced entrepreneurs and seasoned medical device professionals are partnering with an exceptional group of physicians and scientists to develop innovative, cost effective devices that provide physiological feedback to alleviate doubt and uncertainty during common medical procedures.

Nimbic is a provider of SaaS-based, cloud computing electronic design automation (EDA) solutions. Nimbic enables high-speed and high-capacity 3D electromagnetic signal integrity, power integrity and EMI analysis field solutions for the microelectronics industry. Nimbic's global customers include Texas Instruments, Renesas, Toshiba, Tabula and Panasonic. Nimbic's nCloud solution facilitates efficient and robust chip-package-system co-design while significantly reducing time-to-market and costs. Nimbic's accelerated technology delivers unprecedented capacity handling, significantly faster speed than current methodologies, and the ability to span the entire design cycle in 3D IC, package and system simulations, while maintaining uncompromising Maxwell accuracy.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

WiBotic Inc. develops wireless charging and power optimization solutions. It offers wireless charging systems; components, such as transmitters, onboard chargers, antenna coils, and integrated options; accessories for robots, drones, mobile robots, and underwater vehicles; and professional services. In addition, it offers a power management software that works with the hardware to optimize battery use for the fleets of robots. The company serves aerial, mobile, marine, and industrial clients. WiBotic Inc. was incorporated in 2014 and is based in Seattle, Washington.

Users with intelligent airfare predictions

Hyperion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat orphan diseases in the United states, Canada, and internationally. The company offers RAVICTI used as a nitrogen-binding agent for chronic management of urea cycle disorder (UCD) in adult and pediatric patients; and BUPHENYL and AMMONAPS therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate, an active pharmaceutical ingredient in RAVICTI to treat hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California. As of May 7, 2015, Hyperion Therapeutics, Inc. operates as a subsidiary of Horizon Pharma USA, Inc.

Phytelligence is a product-focused technology company that develops and provides smart plants and solutions to growers, nurseries, and horticultural experts. It provides custom genetic analysis services that assess the similarity or dissimilarity of closely related samples. The company provides plants free of diseases, viruses, and pests. Its portfolio includes the Geneva series, Gisela series, and Krymsk series of rootstocks. Phytelligence was founded in 2012 by Amit Dhingra, and it is based in Pullman, Washington.

In the spring of 2002, Vanson, Inc. and HaloSource Corp. merged to form Vanson HaloSource, Inc. in order to expand opportunities for product commercialization by capitalizing on manufacturing facilities, distribution channels and intellectual property. Vanson’s cGMP certified manufacturing facility, located in Western Washington accommodates the production of most of Vanson HaloSource's products. The management team and a talented pool of chemists, biochemists and microbiologists are working together to create and expand the Company’s broad spectrum of applications. Today the Company holds dozens of patents and patents pending on a broad range of products that are distributed to the pool and spa, wastewater treatment, and biomedical industries. The Company has a substantial pipeline of proprietary new products in research and development, and a growing number of strategic alliances with prestigious companies to manufacture and market value-added chitin/chitosan-based and antimicrobial products.

Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.

A-Alpha Bio provides cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio's product, AlphaSeq, is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.

Corensic provides software quality tools and runtimes that enable developers and IT organizations to build and deploy more reliable software. Corensic was founded in late 2008 (formerly known as PetraVM) and backed by Madrona Ventures, the Washington Research Foundation, and Perkins Coie. Our mission is to fuel the multi-core revolution by enabling software developers and IT organizations to build higher quality software. Corensic’s first product is Jinx, a tool that will help you improve the quality of your applications when they are running in a multi-core environment. Jinx makes your code “unlucky” by forcing hard-to-find concurrency bugs to occur with more frequency while you are debugging.

AnswerDash, Inc. provides Website contextual answer services. It enables companies to provide selection-based, self-service, point-and-click contextual answers on their Websites, Web applications, and mobile experiences to their customers where they need them, whether on desktop or mobile platforms. AnswerDash, Inc. was formerly known as Qazzow, Inc. and changed its name to AnswerDash, Inc. in May 2014. The company was founded in 2012 and is based in Seattle, Washington. As of June 23, 2020, AnswerDash, Inc. operates as a subsidiary of CloudEngage, Inc.

MDmetrix is a healthcare data analytics, visualization, and AI company that serves hospitals and surgery centers. By empowering medical leaders and frontline clinicians to access, analyze, and improve clinical and workflow outcomes, MDmetrix enables providers to improve care and lower costs, transforming clinical operations. Founded in Seattle in 2016, MDmetrix was spun out of Seattle Children's Hospital.

Skytap, Inc. provides cloud based development and test environments for migrating and modernizing enterprise applications worldwide. It offers Skytap Cloud, a solution that provides self-service access to production-like environments, which enables development/test teams to test code more frequently. The company’s collaboration tools enable development teams to identify, share, and reproduce software defects. In addition, it offers cloud migration, DevOps, application modernization, training, and independent software vendor solutions; and onboarding and adoption, implementation, and strategic consulting services. Skytap, Inc. was formerly known as illumita, Inc. and changed its name to Skytap, Inc. in April 2008. The company was founded in 2006 and is headquartered in Seattle, Washington. It has other locations in Toronto, Canada; and London, United Kingdom.

Targeted Growth is a crop-biotech company developing yield-enhanced and quality-improved products for the agriculture and energy industries. TGI's crop biotechnology increases the yields in multiple crops and it focuses on those crops such as corn, soy, and canola that produce the raw material that enables farmers to use them for the production of renewable fuels such as ethanol and biodiesel.

Nexgenia, Inc., a biotechnology company, focuses on the development and manufacture of proprietary polymer-based reagents. It develops stimuli-responsive polymers and polymer-containing magnetic nanoparticles for therapeutic and diagnostic applications. The company was incorporated in 2011 and is based in Seattle, Washington.

FlexMinder is revolutionizing the healthcare industry by changing the way third party administrators (TPAs) handle claims, and helping consumers fall in love with their flexible spending arrangements and healthcare reimbursement accounts. FlexMinder automates the claims submission process for participants and helps TPAs dramatically reduce manual processing time and costs. Based in Seattle, Washington, FlexMinder was selected in 2011 to participate in the prestigious TechStars incubator program, and announced $1.4 million in Series AA financing to fund future growth in January 2013.

C-SATS provides a personalized surgical skills assessment platform using a unique combination of data analytics, artificial intelligence. It specializes in the fields of robotic surgery, surgical skills, surgical insights, laparoscopic surgery, and minimally invasive surgery. The company was founded in 2014 and headquartered in Seattle, Washington.

Mirador Biomedical's team of experienced entrepreneurs and seasoned medical device professionals are partnering with an exceptional group of physicians and scientists to develop innovative, cost effective devices that provide physiological feedback to alleviate doubt and uncertainty during common medical procedures.

Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Users with intelligent airfare predictions

AbSci, LLC develops protein production technologies for the biopharmaceutical industry. The company offers SoluPro, a genetically engineered E. coli-based expression system that enables optimizable and scalable production of antibodies, antibody fragments, and other soluble recombinant proteins to be produced at a fraction of their current cost. Its therapeutic proteins and antibodies are used in cancer and hormone therapies, as well as autoimmune and blood disorder therapies. The company was founded in 2011 and is based in Portland, Oregon.

Users with intelligent airfare predictions

Targeted Growth is a crop-biotech company developing yield-enhanced and quality-improved products for the agriculture and energy industries. TGI's crop biotechnology increases the yields in multiple crops and it focuses on those crops such as corn, soy, and canola that produce the raw material that enables farmers to use them for the production of renewable fuels such as ethanol and biodiesel.

Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. In addition, this antibiotic formulation has activity on biofilms. The combination also has activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This formulation is administered using a single-patient use, vibrating-plate nebulizer that is compatible with all ventilators. The nebulizer creates small, uniform aerosol droplets that deliver drug to the small airways and alveoli. Integration of this novel antibiotic formulation and device has the potential to achieve significant clinical outcomes relative to current standard therapy.

Phase Genomics, Inc., a biotechnology company, develops technology for ProxiMeta Hi-C genome assemby and metagenome deconvolution. The company was founded in 2015 and is based in Seattle, Washington.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.

Founded in 2003, Accelerator Corporation is a Seattle-headquartered private equity firm with an office in New York and San Diego. The firm is focused on early-stage investments in biotechnology companies.

FlexMinder is revolutionizing the healthcare industry by changing the way third party administrators (TPAs) handle claims, and helping consumers fall in love with their flexible spending arrangements and healthcare reimbursement accounts. FlexMinder automates the claims submission process for participants and helps TPAs dramatically reduce manual processing time and costs. Based in Seattle, Washington, FlexMinder was selected in 2011 to participate in the prestigious TechStars incubator program, and announced $1.4 million in Series AA financing to fund future growth in January 2013.

GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.

Resolve Therapeutics is a private biotechnology company that is dedicated to the goal of improving the lives of patients suffering from lupus. They are focused on the advancement their exciting, novel biologic compound, RSLV-125 from preclinical research through a phase IIa clinical trial. The company is based on the pioneering discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter in their laboratories at the University of Washington School of Medicine.

Skytap, Inc. provides cloud based development and test environments for migrating and modernizing enterprise applications worldwide. It offers Skytap Cloud, a solution that provides self-service access to production-like environments, which enables development/test teams to test code more frequently. The company’s collaboration tools enable development teams to identify, share, and reproduce software defects. In addition, it offers cloud migration, DevOps, application modernization, training, and independent software vendor solutions; and onboarding and adoption, implementation, and strategic consulting services. Skytap, Inc. was formerly known as illumita, Inc. and changed its name to Skytap, Inc. in April 2008. The company was founded in 2006 and is headquartered in Seattle, Washington. It has other locations in Toronto, Canada; and London, United Kingdom.

Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

Skytap, Inc. provides cloud based development and test environments for migrating and modernizing enterprise applications worldwide. It offers Skytap Cloud, a solution that provides self-service access to production-like environments, which enables development/test teams to test code more frequently. The company’s collaboration tools enable development teams to identify, share, and reproduce software defects. In addition, it offers cloud migration, DevOps, application modernization, training, and independent software vendor solutions; and onboarding and adoption, implementation, and strategic consulting services. Skytap, Inc. was formerly known as illumita, Inc. and changed its name to Skytap, Inc. in April 2008. The company was founded in 2006 and is headquartered in Seattle, Washington. It has other locations in Toronto, Canada; and London, United Kingdom.

MDmetrix is a healthcare data analytics, visualization, and AI company that serves hospitals and surgery centers. By empowering medical leaders and frontline clinicians to access, analyze, and improve clinical and workflow outcomes, MDmetrix enables providers to improve care and lower costs, transforming clinical operations. Founded in Seattle in 2016, MDmetrix was spun out of Seattle Children's Hospital.

Arzeda develops enzyme design technology that presents a new way of thinking about biocatalysis. The company was founded by David Baker and three senior members of his lab to commercialize and further develop its computational enzyme design technology.

VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company's technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.

Rodeo Therapeutics Corp. is a drug development company. The company develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It develops drugs for tissue repair and regeneration. The company was incorporated in 2017 and is based in Seattle, Washington.

Medcurity is a developer of a compliance management platform used to perform complex HIPAA and security requirements for healthcare systems. Its platform enables users to build or complement their HIPAA privacy and security program with the intuitive tools and helpful guides available.

Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.

HyperSciences, Inc develops and manufactures high-velocity drilling solutions for drilling, tunneling, energy, and transportation applications. It offers HyperDrill, an oil and gas and geothermal drilling solution that increases rate of penetration by up to 10x that of existing drilling technology. The company also provides, a geothermal solution that leverages HyperDrill to reach deep geothermal energy deposits; and HyperBreaker, a near surface rock breaking solution for the construction, mining, and tunneling industries. The company was founded in 2014 and is based in Spokane, Washington with an additional office in Austin, Texas.

Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.

AAVogen is a biotech startup that develops gene therapeutics for muscle wasting diseases. This includes muscular dystrophy, inflammatory myopathies and cancer cachexia. We make you stronger.

Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Noting the growing trends in group travel, [Expedia](http://www.crunchbase.com/organization/expedia) and [Microsoft](http://www.crunchbase.com/organization/microsoft) vets founded TripHub in 2005. Based on the philosophy that "planning should be as fun as the trip," TripHub provides users with many different ways to facilitate group travel. Recently, Triphub [teamed up](http://about.triphub.com/2006/01/plan-talk-among.html) with [Orbitz](http://www.orbitz.com) to provide a ["powered by Triphub"](http://about.triphub.com/partners/index.html)group travel option. They are funded by Madrona Venture Group and other private investors. ###TripHub entered the deadpool on August 25, 2008.###

Teranode's software and services support both executives and researchers on research and development decisions. Its goal has been to change the role computing plays in Life Sciences by providing flexible, scientist-driven technology that automates experiment workflow, manages experiment and biological data, unifies data into user specific views to improve product life cycle.

Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Nimbic is a provider of SaaS-based, cloud computing electronic design automation (EDA) solutions. Nimbic enables high-speed and high-capacity 3D electromagnetic signal integrity, power integrity and EMI analysis field solutions for the microelectronics industry. Nimbic's global customers include Texas Instruments, Renesas, Toshiba, Tabula and Panasonic. Nimbic's nCloud solution facilitates efficient and robust chip-package-system co-design while significantly reducing time-to-market and costs. Nimbic's accelerated technology delivers unprecedented capacity handling, significantly faster speed than current methodologies, and the ability to span the entire design cycle in 3D IC, package and system simulations, while maintaining uncompromising Maxwell accuracy.

Arzeda develops enzyme design technology that presents a new way of thinking about biocatalysis. The company was founded by David Baker and three senior members of his lab to commercialize and further develop its computational enzyme design technology.

AnswerDash, Inc. provides Website contextual answer services. It enables companies to provide selection-based, self-service, point-and-click contextual answers on their Websites, Web applications, and mobile experiences to their customers where they need them, whether on desktop or mobile platforms. AnswerDash, Inc. was formerly known as Qazzow, Inc. and changed its name to AnswerDash, Inc. in May 2014. The company was founded in 2012 and is based in Seattle, Washington. As of June 23, 2020, AnswerDash, Inc. operates as a subsidiary of CloudEngage, Inc.

HaloSource Corporation, a clean water technology company, develops and manufactures products for drinking water treatment solutions worldwide. The company’s technologies are based upon proprietary polymer chemistries that can be applied to commonplace synthetic starting materials in a range of applications. It offers gravity devices, including HaloPure disinfecting pitchers that provide germ-free drinking water at home or office; HaloPure pitcher cartridges, which offer treated drinking water at home or office; and HaloPure under-the-candle cartridges. The company also provides pressurized devices comprising HaloPure bacteriostatic water cartridge, a water treatment catridge for use in drinking-water devices; HaloPure heterotroph control cartridges for RO systems; and HaloPure ceramic candle inserts. In addition, it offers mobi-pure line of disinfection hydration products under the astrea brand name. The company was incorporated in 2017 and is headquartered in Bothell, the United States.